



Piattaforma Italiana per lo studio della Terapia delle Epatiti virali.

## Baseline characteristics of patients treated with Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir and Elbasvir/Grazoprevir

		SOF/VEL (N=1208*)		GLE/PIB (N=754*)		ELB/GRA (N=541*)	
		N.	%	N.	%	N.	%
Age	<= 40	75	6.2	68	9.0	21	3.9
	41-50	155	12.8	133	17.6	59	10.9
	51-60	304	25.2	224	29.7	124	22.9
	61-70	266	22.0	156	20.7	137	25.3
	> 70	408	33.8	173	22.9	200	37.0
Median age years (IQR)		63 (53 - 74)		58 (50 - 70)		66 (55 - 74)	
Sex	Male	617	51.1	389	51.6	248	45.8
	Female	591	48.9	365	48.4	293	54.2
BMI	Underweight-Normal	626	51.8	443	58.8	282	52.2
	Overweight-Obese	582	48.2	310	41.2	258	47.8
Steatosis	Yes	387	32.0	255	33.8	187	34.6
	No	821	68.0	499	66.2	354	65.4
Previous Interferon use	Yes	246	20.4	182	24.1	143	26.4
	No	962	79.6	572	75.9	398	73.6
History of <u>previous HCC</u>	Yes	21	1.7	5	0.7	2	0.4
	No	1187	98.3	749	99.3	539	99.6
Potential metabolic syndrome	Yes	200	16.6	97	12.9	100	18.5
	No	1008	83.4	657	87.1	441	81.5
Case-type	F0-F1	544	50.5	460	71.3	261	55.1
	F2	169	15.7	97	15.0	96	20.3
	F3	79	7.3	44	6.8	42	8.9
	F4-Cirrhosis	285	26.5	44	6.8	75	15.8
Child	A	219	80.5	36	87.8	66	93.0
	B	53	19.5	5	12.2	5	7.0
Past decompensations	Yes	40	3.3	6	0.8	4	0.7
	No	1168	96.7	748	99.2	537	99.3
HCV- genotype	1a	158	13.1	118	15.6	45	8.3
	1b	368	30.5	314	41.6	463	85.6
	2	427	35.3	188	24.9	3	0.6
	3	178	14.7	76	10.1	0	0.0
	<u>Other</u>	77	6.4	58	7.7	30	5.5
<u>HIV Infection</u>	Yes	102	8.4	25	3.3	14	2.6
	No	1106	91.6	729	96.7	527	97.4
<u>HBV Infection</u>	No	888	73.5	569	75.5	418	77.3
	<u>Anti-HBc+/HBsAg+</u>	15	1.2	6	0.8	7	1.3
	<u>Anti-HBc+/HBsAg-</u>	305	25.2	179	23.7	116	21.4



Piattaforma Italiana per lo studio  
della Terapia delle Epatiti virali.

## Comorbidities of patients treated with Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir and Elbasvir/Grazoprevir

		SOF/VEL (N=1208)		GLE/PIB (N=754)		ELB/GRA (N=541)	
		N.	%	N.	%	N.	%
<b>Comorbidities</b>							
Diabetes	Yes	159	13.2	41	5.4	68	12.6
	No	1049	86.8	713	94.6	473	87.4
Cardiovascular	Yes	573	47.4	252	33.4	253	46.8
	No	635	52.6	502	66.6	288	53.2
Cerebrovascular	Yes	29	2.4	14	1.9	8	1.5
	No	1179	97.6	740	98.1	533	98.5
Autoimmune/Rheumatic Osteoarticular	Yes	64	5.3	42	5.6	43	7.9
	No	1144	94.7	712	94.4	498	92.1
<u>Haematological</u>	Yes	66	5.5	37	4.9	26	4.8
	No	1142	94.5	717	95.1	515	95.2
<u>Dyslipidemia</u>	Yes	84	7.0	54	7.2	34	6.3
	No	1124	93.0	700	92.8	507	93.7
Endocrine	Yes	117	9.7	70	9.3	65	12.0
	No	1091	90.3	684	90.7	476	88.0
<u>Neurological</u>	Yes	46	3.8	18	2.4	19	3.5
	No	1162	96.2	736	97.6	522	96.5
<u>Psychiatric</u>	Yes	137	11.3	69	9.2	51	9.4
	No	1071	88.7	685	90.8	490	90.6
<u>Renal</u>	Yes	21	1.7	26	3.4	28	5.2
	No	1187	98.3	728	96.6	513	94.8
<u>Respiratory</u>	Yes	45	3.7	28	3.7	17	3.1
	No	1163	96.3	726	96.3	524	96.9
Digestive	Yes	60	5.0	46	6.1	38	7.0
	No	1148	95.0	708	93.9	503	93.0
<u>Dermatologic</u>	Yes	30	2.5	12	1.6	11	2.0
	No	1178	97.5	742	98.4	530	98.0
<u>Solid tumor</u>	Yes	84	7.0	51	6.8	47	8.7
	No	1124	93.0	703	93.2	494	91.3
<u>Hematopoietic/Lymphatic tumors</u>	Yes	22	1.8	7	0.9	8	1.5
	No	1186	98.2	747	99.1	533	98.5
Number of comorbidities	0	354	29.3	310	41.1	167	30.9
	1	431	35.7	224	29.7	173	32.0
	2-3	362	30.0	202	26.8	167	30.9
	≥ 4	61	5.0	18	2.4	34	6.3



Piattaforma Italiana per lo studio della Terapia delle Epatiti virali.

## Baseline characteristics of patients treated with Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir and Elbasvir/Grazoprevir

Year of therapy 2014 - 2017

		SOF/VEL (N=533*)		GLE/PIB (N=82*)		ELB/GRA (N=379*)	
		N.	%	N.	%	N.	%
Age	<= 40	41	7.7	11	13.4	17	4.5
	41-50	93	17.4	18	22.0	45	11.9
	51-60	143	26.8	25	30.5	100	26.4
	61-70	119	22.3	14	17.1	98	25.9
	> 70	137	25.7	14	17.1	119	31.4
Median age years (IQR)		60 (50 - 71)		55 (47 - 65)		64 (54 - 73)	
Sex	Male	283	53.1	42	51.2	182	48.0
	Female	250	46.9	40	48.8	197	52.0
BMI	Underweight-Normal	295	55.3	52	63.4	193	51.1
	Overweight-Obese	238	44.7	30	36.6	185	48.9
Steatosis	Yes	183	34.3	21	25.6	127	33.5
	No	350	65.7	61	74.4	252	66.5
Previous Interferon use	Yes	138	25.9	31	37.8	97	25.6
	No	395	74.1	51	62.2	282	74.4
History of <u>previous HCC</u>	Yes	6	1.1	0	0.0	2	0.5
	No	527	98.9	82	100.0	377	99.5
Potential metabolic syndrome	Yes	92	17.3	9	11.0	63	16.6
	No	441	82.7	73	89.0	316	83.4
Case-type	F0-F1	265	55.0	54	80.6	172	50.7
	F2	91	18.9	9	13.4	74	21.8
	F3	38	7.9	7	3.0	32	9.4
	F4-Cirrhosis	88	18.3	7	3.0	61	18.0
Child	A	64	77.1	2	100.0	52	91.2
	B	19	22.9	0	0.0	5	8.8
Past decompensations	Yes	15	2.8	1	1.2	2	0.5
	No	518	97.2	81	98.8	377	99.5
HCV- genotype	1a	76	14.3	16	19.5	42	11.1
	1b	106	19.9	36	43.9	307	81.0
	2	220	41.3	16	19.5	2	0.5
	3	99	18.6	7	8.5	0	0.0
	Other	32	6.0	7	8.5	28	7.4
HIV <u>Infection</u>	Yes	55	10.3	1	1.2	11	2.9
	No	478	89.7	81	98.8	368	97.1
HBV <u>Infection</u>	No	401	75.2	67	81.7	289	76.3
	Anti-HBc+/HBsAg+	8	1.5	0	0.0	5	1.3
	Anti-HBc+/HBsAg-	124	23.3	15	18.3	85	22.4



Piattaforma Italiana per lo studio  
della Terapia delle Epatiti virali.

## Comorbidities of patients treated with Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir and Elbasvir/Grazoprevir

Year of therapy 2014 - 2017

		SOF/VEL (N=533)		GLE/PIB (N=82)		ELB/GRA (N=379)	
<b>Comorbidities</b>		N.	%	N.	%	N.	%
Diabetes	Yes	49	9.2	5	6.1	43	11.3
	No	484	90.8	77	93.9	336	88.7
Cardiovascular	Yes	213	40.0	26	31.7	162	42.7
	No	320	60.0	56	68.3	217	57.3
Cerebrovascular	Yes	11	2.1	0	0.0	4	1.1
	No	522	97.9	82	100.0	375	98.9
Autoimmune/Rheumatic Osteoarticular	Yes	23	4.3	8	9.8	24	6.3
	No	510	95.7	74	90.2	355	93.7
<u>Haematological</u>	Yes	30	5.6	7	8.5	11	2.9
	No	503	94.4	75	91.5	368	97.1
<u>Dyslipidemia</u>	Yes	29	5.4	8	9.8	17	4.5
	No	504	94.6	74	90.2	362	95.5
Endocrine	Yes	50	9.4	7	8.5	40	10.6
	No	483	90.6	75	91.5	339	89.4
<u>Neurological</u>	Yes	21	3.9	3	3.7	17	4.5
	No	512	96.1	79	96.3	362	95.5
<u>Psychiatric</u>	Yes	51	9.6	5	6.1	30	7.9
	No	482	90.4	77	93.9	349	92.1
<u>Renal</u>	Yes	10	1.9	4	4.9	17	4.5
	No	523	98.1	78	95.1	362	95.5
<u>Respiratory</u>	Yes	15	2.8	4	4.9	10	2.6
	No	518	97.2	78	95.1	369	97.4
Digestive	Yes	34	6.4	11	13.4	25	6.6
	No	499	93.6	71	86.6	354	93.4
<u>Dermatologic</u>	Yes	13	2.4	1	1.2	9	2.4
	No	520	97.6	81	98.8	370	97.6
<u>Solid tumor</u>	Yes	35	6.6	11	13.4	28	7.4
	No	498	93.4	71	86.6	351	92.6
<u>Hematopoietic/Lymphatic tumors</u>	Yes	13	2.4	3	3.7	6	1.6
	No	520	97.6	79	96.3	373	98.4
Number of comorbidities	0	194	36.4	31	37.8	136	35.9
	1	176	33.0	20	24.4	123	32.5
	2-3	136	25.5	27	32.9	103	27.2
	≥ 4	27	5.1	4	4.9	17	4.5

## Baseline characteristics of patients treated with Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir and Elbasvir/Grazoprevir

Year of therapy 2018 - 2023

		SOF/VEL (N=675*)		GLE/PIB (N=672*)		ELB/GRA (N=162*)		
		N.	%	N.	%	N.	%	
Age	<= 40	34	5.0	57	8.5	4	2.5	
	41-50	62	9.2	115	17.1	14	8.6	
	51-60	161	23.9	199	29.6	24	14.8	
	61-70	147	21.8	142	21.1	39	24.1	
	> 70	271	40.1	159	23.7	81	50.0	
Median age years (IQR)		67 (55 - 76)		58 (50 - 70)		71 (59 - 76)		
Sex	Male	334	49.5	347	51.6	66	40.7	
	Female	341	50.5	325	48.4	96	59.3	
BMI	Underweight-Normal	331	49.0	391	58.3	89	54.9	
	Overweight-Obese	344	51.0	280	41.7	73	45.1	
Steatosis	Yes	204	30.2	234	34.8	60	37.0	
	No	471	69.8	438	65.2	102	63.0	
Previous Interferon use	Yes	108	16.0	151	22.5	46	28.4	
	No	567	84.0	521	77.5	116	71.6	
History of previous HCC	Yes	15	2.2	5	0.7	0	0.0	
	No	660	97.8	667	99.3	162	100.0	
Potential metabolic syndrome	Yes	108	16.0	88	13.1	37	22.8	
	No	567	84.0	584	86.9	125	77.2	
Case-type	F0-F1	279	46.9	406	70.2	89	65.9	
	F2	78	13.1	88	15.2	22	16.3	
	F3	41	6.9	42	7.3	10	7.4	
	F4-Cirrhosis	197	33.1	42	7.3	14	10.4	
Child	A	155	82.0	34	87.2	14	100.0	
	B	34	18.0	5	12.8	0	0.0	
Past decompensations	Yes	25	3.7	5	0.7	2	1.2	
	No	650	96.3	667	99.3	160	98.8	
HCV- genotype	1a	82	12.1	102	15.2	3	1.9	
	1b			Riservatezza	278	41.4	156	96.3
	2	207	30.7	172	25.6	1	0.6	
	3	79	11.7	69	10.3	0	0.0	
	Other	45	6.7	51	7.6	2	1.2	
HIV Infection	Yes	47	7.0	24	3.6	3	1.9	
	No	628	93.0	648	96.4	159	98.1	
HBV Infection	No	487	72.1	502	74.7	129	79.6	
	Anti-HBc+/HBsAg+	7	1.0	6	0.9	2	1.2	
	Anti-HBc+/HBsAg-	181	26.8	164	24.4	31	19.1	



Piattaforma Italiana per lo studio della Terapia delle Epatiti virali.

## Comorbidities of patients treated with Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir and Elbasvir/Grazoprevir

Year of therapy 2018 - 2023

		SOF/VEL (N=675)		GLE/PIB (N=672)		ELB/GRA (N=162)	
<b>Comorbidities</b>		N.	%	N.	%	N.	%
Diabetes	Yes	110	16.3	36	5.4	25	15.4
	No	565	83.7	636	94.6	137	84.6
Cardiovascular	Yes	360	53.3	226	33.6	91	56.2
	No	315	46.7	446	66.4	71	43.8
Cerebrovascular	Yes	18	2.7	14	2.1	4	2.5
	No	657	97.3	658	97.9	158	97.5
Autoimmune/Rheumatic Osteoarticular	Yes	41	6.1	34	5.1	19	11.7
	No	634	93.9	638	94.9	143	88.3
<u>Haematological</u>	Yes	36	5.3	30	4.5	15	9.3
	No	639	94.7	642	95.5	147	90.7
<u>Dyslipidemia</u>	Yes	55	8.1	46	6.8	17	10.5
	No	620	91.9	626	93.2	145	89.5
Endocrine	Yes	67	9.9	63	9.4	25	15.4
	No	608	90.1	609	90.6	137	84.6
<u>Neurological</u>	Yes	25	3.7	15	2.2	2	1.2
	No	650	96.3	657	97.8	160	98.8
<u>Psychiatric</u>	Yes	86	12.7	64	9.5	21	13.0
	No	589	87.3	608	90.5	141	87.0
<u>Renal</u>	Yes	11	1.6	22	3.3	11	6.8
	No	664	98.4	650	96.7	151	93.2
<u>Respiratory</u>	Yes	30	4.4	24	3.6	7	4.3
	No	645	95.6	648	96.4	155	95.7
Digestive	Yes	26	3.9	35	5.2	13	8.0
	No	649	96.1	637	94.8	149	92.0
<u>Dermatologic</u>	Yes	17	2.5	11	1.6	2	1.2
	No	658	97.5	661	98.4	160	98.8
<u>Solid tumor</u>	Yes	49	7.3	40	6.0	19	11.7
	No	626	92.7	632	94.0	143	88.3
<u>Hematopoietic/Lymphatic tumors</u>	Yes	9	1.3	4	0.6	2	1.2
	No	666	98.7	668	99.4	160	98.8
Number of comorbidities	0	160	23.7	279	41.5	31	19.1
	1	255	37.8	204	30.4	50	30.9
	2-3	226	33.5	175	26.0	64	39.5
	≥4	34	5.0	14	2.1	17	10.5